Press Release from ORG: ORG (ORG:TWST), a company enabling customers to succeed through ORG offering of high-quality synthetic DNA using ORG silicon platform, today announced https://www.businesswire.com/news/home/20210909005527/en/"ORG Ingelheim.Press Release from ORG features multimedia. View Press Release from ORG here: https://www.businesswire.com/news/home/20210909005527/en/"ORG Ingelheim believes ORG's ability to generate potent, diverse therapeutic antibodies by mining https://www.businesswire.com/news/home/20210909005527/en/"ORG Ingelheim comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable our to deliver breakthrough opportunities to patients," said Wood. "We look forward to working with ORG on molecular targets in a broad range of disease areas," added Wood.Under the terms of the agreement, ORG Biopharma, a division of ORG, will utilize ORG Biopharma "Library of Libraries," a panel of synthetic antibody phage display libraries derived only from sequences that exist in the human body, to identify potential therapeutic antibody candidates. ORG and ORG https://www.businesswire.com/news/home/20210909005527/en/"ORG Ingelheim will work together to validate and optimize any resulting new antibody candidates, which could be researched against a range of therapeutic areas. ORG Ingelheim retains exclusive worldwide rights to develop and commercialize any therapeutic antibodies discovered as part of the collaboration.ORG will receive an upfront payment for each program entry. In addition, ORG has the potential to earn up to a total of $710 million in success-based clinical, regulatory and commercial milestone payments for the multiple target discovery programs."This discovery collaboration with ORG Ingelheim covering numerous targets truly illustrates the power of our antibody libraries. our have the ability to generate precise antibodies to a diverse range of targets, which together with ORG Ingelheim strength in drug development capabilities, could mean multiple new, more personalized treatments in the future for patients," said Emily M. Leproust, Ph.D., CEO and co-founder of ORG.Legal Notice Regarding Forward-Looking StatementsThis press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation ORG's ability to discover novel therapeutic antibodies against multiple targets and to achieve any of the clinical, regulatory or commercial milestones, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause ORG Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products ORG Bioscience's is developing obsolete or non-competitive; the retention of employees of acquired companies and the ability of ORG Bioscience's to successfully integrate acquired companies and to achieve expected benefits, risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate ORG Bioscience's patents or proprietary rights; and the risk that ORG Bioscience's proprietary rights may be insufficient to protect ORG Bioscience's technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ORG Bioscience's business in general, see ORG Bioscience's risk factors set forth in ORG Bioscience's's Quarterly Report Form 10-Q filed with ORG on August 9, 2021 and subsequent filings with the ORG. Any forward-looking statements contained in this press release speak only as of the date hereof, and ORG Bioscience's specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.Please click on the following link for 'Notes to Editors':http://www.boehringer-ingelheim.com/press-release/new-therapeutic-antibody-discovery-collaborationView source version on businesswire.com: https://www.businesswire.com/news/home/20210909005527/en/ContactORG Bioscience Angela Bitting SVP, Corporate Affairs 925- 202-6211 media@twistbioscience.comORG Ingelheim Dr. Reinhard Malin Head of Communications Innovation Unit ORG Ingelheim Corporate Center GmbH Media + PR P: +49 6132 77-90815 press@boehringer-ingelheim.comLinda Ruckel Senior Associate Director, Media and Corporate Reputation ORG Ingelheim U.S. Media + PR P: +1 203-791-6672 press@boehringer-ingelheim.comÂ© 2021 ORG, Inc.Disclaimer:This material is not an ORG editorial material, and ORG shall not bear responsibility for the accuracy of an ORG editorial material content. In case you have any questions about the content, kindly refer to the contact person/entity mentioned in the text of the release.